Oruka Therapeutics (NASDAQ:ORKA) Now Covered by Leerink Partners

Stock analysts at Leerink Partners started coverage on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research note issued on Tuesday, Briefing.com reports. The firm set an “outperform” rating and a $44.00 price target on the stock. Leerink Partners’ price objective points to a potential upside of 69.88% from the stock’s previous close.

Several other research firms also recently weighed in on ORKA. Jefferies Financial Group started coverage on shares of Oruka Therapeutics in a report on Friday. They set a “buy” rating and a $40.00 target price for the company. TD Cowen started coverage on shares of Oruka Therapeutics in a research note on Monday. They set a “buy” rating for the company. Lifesci Capital assumed coverage on Oruka Therapeutics in a research report on Monday. They set an “outperform” rating and a $41.00 price objective for the company. Finally, Wedbush initiated coverage on Oruka Therapeutics in a report on Wednesday, September 4th. They set an “outperform” rating and a $40.00 target price on the stock. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Oruka Therapeutics currently has an average rating of “Buy” and a consensus target price of $41.25.

Oruka Therapeutics Price Performance

Shares of ORKA stock opened at $25.90 on Tuesday. Oruka Therapeutics has a fifty-two week low of $18.72 and a fifty-two week high of $53.88.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.